173 related articles for article (PubMed ID: 23692463)
21. Fluorescence-based experimental model to evaluate the concomitant effect of drugs on the tumour microenvironment and cancer cells.
Ramasamy K; Khatun H; Macpherson L; Caley MP; Sturge J; Mufti GJ; Schey SA; Calle Y
Br J Haematol; 2012 Jun; 157(5):564-79. PubMed ID: 22428569
[TBL] [Abstract][Full Text] [Related]
22. Treatment of relapsed and refractory multiple myeloma in the era of novel agents.
van de Donk NW; Lokhorst HM; Dimopoulos M; Cavo M; Morgan G; Einsele H; Kropff M; Schey S; Avet-Loiseau H; Ludwig H; Goldschmidt H; Sonneveld P; Johnsen HE; Bladé J; San-Miguel JF; Palumbo A
Cancer Treat Rev; 2011 Jun; 37(4):266-83. PubMed ID: 20863623
[TBL] [Abstract][Full Text] [Related]
23. Bortezomib: a valuable new antineoplastic strategy in multiple myeloma.
Bladé J; Cibeira MT; Rosiñol L
Acta Oncol; 2005; 44(5):440-8. PubMed ID: 16118077
[TBL] [Abstract][Full Text] [Related]
24. Novel targeted drugs for the treatment of multiple myeloma: from bench to bedside.
Bruno B; Giaccone L; Rotta M; Anderson K; Boccadoro M
Leukemia; 2005 Oct; 19(10):1729-38. PubMed ID: 16094421
[TBL] [Abstract][Full Text] [Related]
25. From cell biology to therapy: ENMD-2076 in the treatment of multiple myeloma.
Zhang S; Farag SS
Expert Opin Investig Drugs; 2011 Jul; 20(7):1015-28. PubMed ID: 21615212
[TBL] [Abstract][Full Text] [Related]
26. New horizons in multiple myeloma therapy.
Santos ES; Kharfan-Dabaja MA
Expert Rev Anticancer Ther; 2006 Oct; 6(10):1483-501. PubMed ID: 17069532
[TBL] [Abstract][Full Text] [Related]
27. Future drug developments in multiple myeloma: an overview of novel lenalidomide-based combination therapies.
Morgan G
Blood Rev; 2010 Nov; 24 Suppl 1():S27-32. PubMed ID: 21126634
[TBL] [Abstract][Full Text] [Related]
28. Panobinostat for the treatment of multiple myeloma.
Neri P; Bahlis NJ; Lonial S
Expert Opin Investig Drugs; 2012 May; 21(5):733-47. PubMed ID: 22404247
[TBL] [Abstract][Full Text] [Related]
29. [Role of bortezomib in the treatment of multiple myeloma].
Gotoh A; Ohyashiki K
Nihon Rinsho; 2007 Dec; 65(12):2309-14. PubMed ID: 18069278
[TBL] [Abstract][Full Text] [Related]
30. Personalized immunotherapy for the treatment of non-Hodgkin's lymphoma: a promising approach.
Vose JM
Hematol Oncol; 2006 Jun; 24(2):47-55. PubMed ID: 16447298
[TBL] [Abstract][Full Text] [Related]
31. Changing treatment paradigms for patients with plasma cell myeloma: impact upon immune determinants of infection.
Teh BW; Harrison SJ; Pellegrini M; Thursky KA; Worth LJ; Slavin MA
Blood Rev; 2014 Mar; 28(2):75-86. PubMed ID: 24582081
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic use of immunomodulatory drugs in the treatment of multiple myeloma.
Raje N; Hideshima T; Anderson KC
Expert Rev Anticancer Ther; 2006 Sep; 6(9):1239-47. PubMed ID: 17020458
[TBL] [Abstract][Full Text] [Related]
33. Bortezomib for previously untreated multiple myeloma.
Delforge M
Expert Opin Pharmacother; 2011 Nov; 12(16):2553-64. PubMed ID: 21942881
[TBL] [Abstract][Full Text] [Related]
34. New insights, recent advances, and current challenges in the biological treatment of multiple myeloma.
Vallet S; Podar K
Expert Opin Biol Ther; 2013 Jun; 13 Suppl 1():S35-53. PubMed ID: 23768134
[TBL] [Abstract][Full Text] [Related]
35. The emerging role of arsenic trioxide as an immunomodulatory agent in the management of multiple myeloma.
Kalmadi SR; Hussein MA
Acta Haematol; 2006; 116(1):1-7. PubMed ID: 16809883
[TBL] [Abstract][Full Text] [Related]
36. The microenvironment and molecular biology of the multiple myeloma tumor.
Lemaire M; Deleu S; De Bruyne E; Van Valckenborgh E; Menu E; Vanderkerken K
Adv Cancer Res; 2011; 110():19-42. PubMed ID: 21704227
[TBL] [Abstract][Full Text] [Related]
37. CCR1 as a target for multiple myeloma.
Vallet S; Anderson KC
Expert Opin Ther Targets; 2011 Sep; 15(9):1037-47. PubMed ID: 21609295
[TBL] [Abstract][Full Text] [Related]
38. Drug insight: thalidomide as a treatment for multiple myeloma.
Kumar S; Anderson KC
Nat Clin Pract Oncol; 2005 May; 2(5):262-70. PubMed ID: 16264962
[TBL] [Abstract][Full Text] [Related]
39. How to improve the immunogenicity of chemotherapy and radiotherapy.
Ma Y; Conforti R; Aymeric L; Locher C; Kepp O; Kroemer G; Zitvogel L
Cancer Metastasis Rev; 2011 Mar; 30(1):71-82. PubMed ID: 21298323
[TBL] [Abstract][Full Text] [Related]
40. Combined proteasome and histone deacetylase inhibition: A promising synergy for patients with relapsed/refractory multiple myeloma.
Jagannath S; Dimopoulos MA; Lonial S
Leuk Res; 2010 Sep; 34(9):1111-8. PubMed ID: 20472288
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
